Covid Vaccination Argentina

[gracielle]

2 Oct 2021

Rusia afirma que sólo faltan "detalles administrativos" para que la OMS apruebe la Sputnik | Tuits en la cuenta oficial de la vacuna

De acuerdo a la publicación, el dato "ha sido confirmado por el director general de la OMS, Tedros Adhanom Ghebreyesus".

www.pagina12.com.ar

....The official Twitter account of the vaccine stated, quoting the Minister of Health, Mikhail Murashko: "All barriers for the authorization of Sputnik V by the WHO have been eliminated, only minor administrative procedures need to be solved". The tweet also states that the information "has been confirmed by the WHO director general, Tedros Adhanom Ghebreyesus"....

 

[FrankPintor]

"Did Pfizer Peak Too Soon? A decision to go with a lower dose might have helped speed things up last year. Now we may be seeing the consequences".

From https://www.theatlantic.com/health/...r-won-vaccine-race-was-there-downside/620276/ this might serve as an admonishment to those in Argentina who weaponized the negotiations with Pfizer to attack the vaccination program.

"Compared with Moderna’s competing shot, Pfizer’s vaccine seems to induce half the amount of virus-fighting antibodies, and is associated with nearly twice as many breakthrough infections, according to two recent studies".

The discussion on dosing and finding the easiest path through the regulatory process is interesting, concluding with "Three doses of Pfizer, at 30 micrograms each, still amount to less material than a single, 100-microgram dose of Moderna". The higher doses produce more side effects, but it might be worth suffering through the fever and other symptoms some of us have experienced after vaccination: "Phase 3 trials of Moderna’s mRNA vaccine produced very similar efficacy numbers; the only hint of a difference was that Moderna’s more potent shot produced more complaints of fever and headaches", but the protection from Moderna seems to be longer lasting: "“It’s surprising that this enormous group of patients [senior citizens] already needs a new dose of Pfizer".

In other, better, news:

BREAKING | Russia’s Health Minister Mikhail Murashko on #SputnikV @WHO authorization: All barriers for SputnikV authorization by WHO have been removed, only minor administrative procedures need to be sorted. It has been confirmed by @WHO Director-General @DrTedros.

— Sputnik V (@sputnikvaccine) October 2, 2021

 

[gracielle]

2 Oct 2021

Sinopharm para chicos: La ANMAT autorizó el uso de esa vacuna para niños de 3 a 11 años | Hay 10 millones de dosis reservadas para esta franja etaria

La ministra de Salud de la Nación,<b> Carla Vizzotti</b>, anunció este viernes que la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) autorizó el uso de emergencia de la vacuna china Sinopharm contra la covid-19 en niños ...

www.pagina12.com.ar

There are 10 million doses reserved for this age group. Sinopharm for children: ANMAT authorized the use of this vaccine for children from 3 to 11 years of age....

 

[Alby]

"Did Pfizer Peak Too Soon? A decision to go with a lower dose might have helped speed things up last year. Now we may be seeing the consequences".

From https://www.theatlantic.com/health/...r-won-vaccine-race-was-there-downside/620276/ this might serve as an admonishment to those in Argentina who weaponized the negotiations with Pfizer to attack the vaccination program.

"Compared with Moderna’s competing shot, Pfizer’s vaccine seems to induce half the amount of virus-fighting antibodies, and is associated with nearly twice as many breakthrough infections, according to two recent studies".

The discussion on dosing and finding the easiest path through the regulatory process is interesting, concluding with "Three doses of Pfizer, at 30 micrograms each, still amount to less material than a single, 100-microgram dose of Moderna". The higher doses produce more side effects, but it might be worth suffering through the fever and other symptoms some of us have experienced after vaccination: "Phase 3 trials of Moderna’s mRNA vaccine produced very similar efficacy numbers; the only hint of a difference was that Moderna’s more potent shot produced more complaints of fever and headaches", but the protection from Moderna seems to be longer lasting: "“It’s surprising that this enormous group of patients [senior citizens] already needs a new dose of Pfizer".

Interesting.

This postcast talks about a new major preprint study in the UK that shows the initial immunity advantage Pfizer has over AZ disappears at the four-month mark because Pfizer falls away at around 7% per month whereas AZ holds its own. After four months they are equal. The data doesn't yet answer the question about whether Pfizer continues to drop after four months (i.e., whether, eventually, AZ in fact becomes superior).

Are vaccines better at preventing infection than we thought? - ABC listen

Australia's vaccination rate increasing over the weeks has been a thing of beauty to watch, and hopefully soon will help pay out dividends. But along with helping prevent the hospital system from collapsing, vaccines might be better than we thought at helping you avoid catching COVID-19 at all...

www.abc.net.au

 

[FrankPintor]

For any Irish people on this forum, this is being reported now, regarding the COVID certificate scheme will be managed in two phases

“Phase 2 takes place on October 21, when Irish citizens who live outside the European Union will be eligible; provided they have been fully immunised by one of the vaccines on the EMA’s approval list”.

From: https://www.irishpost.com/news/covid-certificates-for-all-irish-passport-holders-who-have-been-vaccinated-221135

https://www.gov.ie/en/publication/3a698-eu-digital-covid-certificate/ also says:

People who have been vaccinated or have recovered in another country

For a two dose vaccine schedule, if you received the first dose abroad and the second dose in Ireland, you may apply for an EU Digital COVID Certificate in Ireland. In this case you will need to contact the service centre and provide evidence of your first vaccine abroad.

If you received your first dose in Ireland and your second dose in another country, then please apply to the country where you received your second dose for a certificate.

If you received your complete vaccine schedule in a third country outside the EU, but are an Irish citizen, a mechanism is being developed to issue an EU Digital COVID Certificate. More details will be added about this in due course.

 

[gracielle]

2 Oct 2021

Sinopharm para chicos: La ANMAT autorizó el uso de esa vacuna para niños de 3 a 11 años | Hay 10 millones de dosis reservadas para esta franja etaria

La ministra de Salud de la Nación,<b> Carla Vizzotti</b>, anunció este viernes que la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) autorizó el uso de emergencia de la vacuna china Sinopharm contra la covid-19 en niños ...

www.pagina12.com.ar

There are 10 million doses reserved for this age group. Sinopharm for children: ANMAT authorized the use of this vaccine for children from 3 to 11 years of age....

UPDATE:
26 August 2021

Vacunados con Sinopharm necesitarían una tercera dosis - Radiocanal - San Francisco Córdoba Argentina

La patóloga argentina Marta Cohen, quien reside en el Reino Unido, dijo que aunque está comprobada su eficacia, es de "corta duración".

www.radiocanal.com.ar

Those vaccinated with Sinopharm would need a third dose. The Argentinean pediatric pathologist Marta Cohen, who resides in the UK, said that although its efficacy has been proven, it is "short-lived". She indicated that those who have received the Chinese vaccine, Sinopharm, should reinforce it with a third dose of the same vaccine or combine it with another laboratory. "All inactivated virus vaccines are effective but short-lived," she clarified and considered that "at five months a third dose of Sinopharm or another vaccine should be given," but she remarked that she does not know if the Argentine gov't is considering it. Cohen reminded that this booster of the Chinese vaccine has already been used in the Arab Emirates, where it was combined with Pfizer doses. Meanwhile, in Uruguay, where the Sinovac vaccine, of similar technology to Sinopharm, was administered, a third dose was also applied. To date, it is the most widely used vaccine in the country....

1 Oct 2021
Coronavirus: Sinopharm vaccine authorized for children from 3 to 11 years of age - Interview with Dr. Marta Cohen by Pablo Rossi, LaNacion+

 

[gracielle]

3 October 2021

Sociedad de Infectología Pediátrica avaló la vacunación en menores, pero quiere ver las pruebas

La organización señaló que si bien “los datos publicados de Sinopharm son alentadores, es imprescindible disponer de la información científica” de la Dirección Nacional de Evaluación y Registros de Medicamentos, dependiente del Gobierno nacional.

www.perfil.com

Society of Pediatric Infectious Diseases endorsed vaccination in minors between the ages of 3 and 11, but wants to see the evidence. The organization pointed out that although "the data published by Sinopharm are encouraging, it is essential to have the scientific information" from the National Directorate for the Evaluation and Registration of Medicines, which is a dependency of the national gov't.

...."Although the impact of Covid-19 in pediatrics has been less than in other groups, the risk increases with the emergence of new variants and the increase in the vulnerable population. Therefore, we agree with vaccination in children under 12 years of age, as they are a vulnerable population," the SADIP statement said. In the text, signed by its president, María Marta Contrini, and vice-president, Gustavo Ezcurra, it added: "It is necessary to move forward with safe and effective vaccines, approved by international regulatory authorities: World Health Organization (WHO), European Medicines Agency (EMA), United States Food and Drug Administration (FDA)". And finally, they specified that "although the data published from the Phase I and II studies of the Sinopharm vaccine are encouraging, it is essential to have the scientific information referred to, from the National Directorate for the Evaluation and Registration of Medicines", at the same time they requested that "the complementary technical report on the Sinopharm vaccine for its use from 3 years of age should be extended".

The same position as the SADIP was taken by the Argentine Society of Pediatrics, which said it was in favor of the measure but remarked: "We hope to have access in the next few days to the scientific evidence that has allowed the ANMAT to authorize the National Ministry of Health to use, in an emergency situation, the inactivated Synopharm virus vaccine in the population aged 3 to 11 years". "We advise starting vaccination in children under 12 years of age with prioritized groups, established on the basis of comorbidities, in a similar way to the population aged 12 to 17 years," added the statement, signed by the president of the SAP, Omaer Tabacco.

 

[gracielle]

4 October 2021

EU medicines agency approves Covid-19 booster vaccine for all adults

The European Medicines Agency has given its approval for a third Pfizer Covid-19 vaccine for all adults in order to increase immunity levels, paving the way for booster jabs to be rolled out across the EU.

www.thelocal.it

The European Medicines Agency has given its approval for a third Pfizer Covid-19 vaccine for all adults age 18 and over in order to increase immunity levels, paving the way for booster jabs to be rolled out across the EU. It is studying data to see whether a third Moderna jab could also be administered as a booster vaccine.

The extra jab could be given at least six months after the individual received their second dose of the vaccine. “The CHMP has evaluated data for Comirnaty (Pfizer/BioNTech) showing a rise in antibody levels when a booster dose is given approximately 6 months after the second dose in people from 18 to 55 years old,” read the EMA statement....It also concluded that an extra dose of the Pfizer or Moderna COVID-19 vaccines may be given to people with severely weakened immune systems, at least 28 days after their second dose....Each country in the EU has implemented its own policy towards Covid-19 vaccines and that goes for booster shots. Certain countries have already began booster campaigns for elderly residents with weakened immune systems....

 

[gracielle]

4 October 2021

Covid: Carla Vizzotti confirmó que el 12 de octubre comenzará la vacunación a chicos de 3 a 11 años con Sinopharm

Se dará prioridad a los niños con factores de riesgo. La ministra hizo el anuncio junto al presidente de la Sociedad Argentina de Pediatría, tras la polémica por el uso pediátrico de este vacuna. Vacunas en las escuelas bonaerenses: será opcional para chicos de 3 a 11 años

www.clarin.com

Covid: Carla Vizzotti confirmed that vaccination of children from 3 to 11 years of age with Sinopharm will begin on October 12. Priority will be given to children with risk factors. The Minister of Health made the announcement together with the President of the Argentine Society of Pediatrics, after the controversy over the pediatric use of this vaccine....

 

[gracielle]

5 October 2021

Aprueban de emergencia una vacuna para chicos desde 12 años: cuál es

Ya es oficial el uso de la vacuna Moderna en chicos adolescentes menores de 18 años. Se empezó a aplicar a fines de julio en jóvenes de 12 a 17 años con comorbilidades. Cuál es la eficacia en chicos.

www.cronista.com

Official Bulletin. Moderna vaccine approved for children from 12 to 17 years of age: the Gov't authorized its emergency use.
It started to be applied at the end of July in youngsters from 12 to 17 years old with comorbidities. What is the efficacy in children. The decision is the result of the fact that the ANMAT "evaluated the drug with a favorable result". That is to say, it is considered that it complies with the "parameters of safety, immunogenicity and efficacy acceptable for age groups over 12 years old"....According to the report, "the results of the Phase 3 efficacy analysis provided for the group over 18 years of age showed 94.1%", while in those over 65 years of age it is 86.4%. The United States, Canada, the United Kingdom, Israel, the European Union and the World Health Organization all endorse Moderna....